nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—HTR2C—bipolar disorder	0.218	0.291	CbGaD
Ergotamine—HTR1A—bipolar disorder	0.211	0.283	CbGaD
Ergotamine—DRD2—bipolar disorder	0.179	0.24	CbGaD
Ergotamine—HTR2A—bipolar disorder	0.139	0.186	CbGaD
Ergotamine—SLC6A2—locus ceruleus—bipolar disorder	0.0074	0.0985	CbGeAlD
Ergotamine—HTR2A—locus ceruleus—bipolar disorder	0.00445	0.0592	CbGeAlD
Ergotamine—HTR1B—telencephalic ventricle—bipolar disorder	0.00439	0.0584	CbGeAlD
Ergotamine—HTR1D—telencephalic ventricle—bipolar disorder	0.00425	0.0565	CbGeAlD
Ergotamine—HTR2C—telencephalic ventricle—bipolar disorder	0.00421	0.0559	CbGeAlD
Ergotamine—SLC6A2—autonomic nervous system—bipolar disorder	0.00393	0.0523	CbGeAlD
Ergotamine—HTR1A—telencephalic ventricle—bipolar disorder	0.00354	0.0471	CbGeAlD
Ergotamine—DRD2—telencephalic ventricle—bipolar disorder	0.0032	0.0425	CbGeAlD
Ergotamine—CYP1A2—urine—bipolar disorder	0.00246	0.0328	CbGeAlD
Ergotamine—HTR2A—autonomic nervous system—bipolar disorder	0.00236	0.0314	CbGeAlD
Ergotamine—HTR2A—telencephalic ventricle—bipolar disorder	0.00211	0.0281	CbGeAlD
Ergotamine—HTR2A—urine—bipolar disorder	0.00193	0.0256	CbGeAlD
Ergotamine—CYP3A4—urine—bipolar disorder	0.00178	0.0237	CbGeAlD
Ergotamine—HTR1A—blood plasma—bipolar disorder	0.00169	0.0224	CbGeAlD
Ergotamine—HTR1F—nervous system—bipolar disorder	0.00152	0.0202	CbGeAlD
Ergotamine—HTR1E—nervous system—bipolar disorder	0.00131	0.0175	CbGeAlD
Ergotamine—CYP1A2—blood plasma—bipolar disorder	0.00129	0.0171	CbGeAlD
Ergotamine—ADRA2A—blood plasma—bipolar disorder	0.00118	0.0157	CbGeAlD
Ergotamine—HTR1F—brain—bipolar disorder	0.00116	0.0154	CbGeAlD
Ergotamine—HTR2A—blood plasma—bipolar disorder	0.00101	0.0134	CbGeAlD
Ergotamine—HTR1E—brain—bipolar disorder	0.001	0.0134	CbGeAlD
Ergotamine—HTR2B—adrenal cortex—bipolar disorder	0.000956	0.0127	CbGeAlD
Ergotamine—CYP3A4—blood plasma—bipolar disorder	0.000931	0.0124	CbGeAlD
Ergotamine—ADRA1B—nervous system—bipolar disorder	0.000823	0.011	CbGeAlD
Ergotamine—ADRA1D—nervous system—bipolar disorder	0.000805	0.0107	CbGeAlD
Ergotamine—Ergoloid mesylate—DRD1—bipolar disorder	0.000747	0.0825	CrCbGaD
Ergotamine—Lisuride—DRD5—bipolar disorder	0.000701	0.0774	CrCbGaD
Ergotamine—HTR2B—thyroid gland—bipolar disorder	0.000666	0.00886	CbGeAlD
Ergotamine—ABCB1—blood plasma—bipolar disorder	0.000659	0.00877	CbGeAlD
Ergotamine—Bromocriptine—DRD5—bipolar disorder	0.00065	0.0717	CrCbGaD
Ergotamine—ADRA1B—brain—bipolar disorder	0.000629	0.00837	CbGeAlD
Ergotamine—HTR1B—nervous system—bipolar disorder	0.000622	0.00827	CbGeAlD
Ergotamine—ADRA1D—brain—bipolar disorder	0.000616	0.00819	CbGeAlD
Ergotamine—HTR1D—nervous system—bipolar disorder	0.000602	0.00801	CbGeAlD
Ergotamine—HTR2C—nervous system—bipolar disorder	0.000596	0.00793	CbGeAlD
Ergotamine—HTR2B—nervous system—bipolar disorder	0.00056	0.00745	CbGeAlD
Ergotamine—Ergoloid mesylate—DRD2—bipolar disorder	0.000527	0.0582	CrCbGaD
Ergotamine—HTR1A—nervous system—bipolar disorder	0.000502	0.00668	CbGeAlD
Ergotamine—SLC6A2—nervous system—bipolar disorder	0.000498	0.00662	CbGeAlD
Ergotamine—HTR1B—brain—bipolar disorder	0.000475	0.00632	CbGeAlD
Ergotamine—HTR1A—cerebellum—bipolar disorder	0.000472	0.00628	CbGeAlD
Ergotamine—Dihydroergotamine—HTR1A—bipolar disorder	0.00047	0.0519	CrCbGaD
Ergotamine—ADRA1A—nervous system—bipolar disorder	0.000463	0.00615	CbGeAlD
Ergotamine—HTR1D—brain—bipolar disorder	0.00046	0.00612	CbGeAlD
Ergotamine—HTR2C—brain—bipolar disorder	0.000456	0.00606	CbGeAlD
Ergotamine—CYP1A2—thyroid gland—bipolar disorder	0.000455	0.00605	CbGeAlD
Ergotamine—DRD2—nervous system—bipolar disorder	0.000453	0.00603	CbGeAlD
Ergotamine—Methylergometrine—DRD1—bipolar disorder	0.000453	0.05	CrCbGaD
Ergotamine—Ergonovine—HTR2C—bipolar disorder	0.000443	0.0489	CrCbGaD
Ergotamine—ADRA1A—cerebellum—bipolar disorder	0.000435	0.00579	CbGeAlD
Ergotamine—HTR2B—brain—bipolar disorder	0.000428	0.00569	CbGeAlD
Ergotamine—DRD2—cerebellum—bipolar disorder	0.000427	0.00568	CbGeAlD
Ergotamine—ADRA2A—thyroid gland—bipolar disorder	0.000418	0.00556	CbGeAlD
Ergotamine—Methylergometrine—HTR2C—bipolar disorder	0.000387	0.0428	CrCbGaD
Ergotamine—HTR1A—brain—bipolar disorder	0.000384	0.0051	CbGeAlD
Ergotamine—SLC6A2—brain—bipolar disorder	0.00038	0.00506	CbGeAlD
Ergotamine—Lisuride—DRD4—bipolar disorder	0.000359	0.0396	CrCbGaD
Ergotamine—ADRA1A—brain—bipolar disorder	0.000354	0.0047	CbGeAlD
Ergotamine—ADRA2A—nervous system—bipolar disorder	0.000352	0.00468	CbGeAlD
Ergotamine—DRD2—brain—bipolar disorder	0.000347	0.00461	CbGeAlD
Ergotamine—ABCB1—adrenal cortex—bipolar disorder	0.000334	0.00445	CbGeAlD
Ergotamine—Bromocriptine—DRD4—bipolar disorder	0.000332	0.0367	CrCbGaD
Ergotamine—ADRA2A—cerebellum—bipolar disorder	0.000331	0.0044	CbGeAlD
Ergotamine—Methysergide—HTR2C—bipolar disorder	0.000323	0.0357	CrCbGaD
Ergotamine—Methysergide—HTR1A—bipolar disorder	0.000314	0.0347	CrCbGaD
Ergotamine—Lisuride—DRD3—bipolar disorder	0.000309	0.0342	CrCbGaD
Ergotamine—Lisuride—DRD1—bipolar disorder	0.000304	0.0335	CrCbGaD
Ergotamine—HTR2A—nervous system—bipolar disorder	0.000299	0.00398	CbGeAlD
Ergotamine—Bromocriptine—DRD3—bipolar disorder	0.000287	0.0316	CrCbGaD
Ergotamine—HTR2A—cerebellum—bipolar disorder	0.000281	0.00374	CbGeAlD
Ergotamine—Bromocriptine—DRD1—bipolar disorder	0.000281	0.0311	CrCbGaD
Ergotamine—CYP3A4—nervous system—bipolar disorder	0.000277	0.00368	CbGeAlD
Ergotamine—ADRA2A—brain—bipolar disorder	0.000269	0.00358	CbGeAlD
Ergotamine—Lisuride—HTR2C—bipolar disorder	0.00026	0.0287	CrCbGaD
Ergotamine—Lisuride—HTR1A—bipolar disorder	0.000252	0.0278	CrCbGaD
Ergotamine—Methylergometrine—HTR2A—bipolar disorder	0.000247	0.0272	CrCbGaD
Ergotamine—Bromocriptine—HTR2C—bipolar disorder	0.000241	0.0266	CrCbGaD
Ergotamine—Bromocriptine—HTR1A—bipolar disorder	0.000234	0.0258	CrCbGaD
Ergotamine—ABCB1—thyroid gland—bipolar disorder	0.000233	0.0031	CbGeAlD
Ergotamine—HTR2A—brain—bipolar disorder	0.000229	0.00304	CbGeAlD
Ergotamine—Lisuride—DRD2—bipolar disorder	0.000214	0.0236	CrCbGaD
Ergotamine—Methysergide—HTR2A—bipolar disorder	0.000206	0.0227	CrCbGaD
Ergotamine—Bromocriptine—DRD2—bipolar disorder	0.000198	0.0219	CrCbGaD
Ergotamine—ABCB1—nervous system—bipolar disorder	0.000196	0.00261	CbGeAlD
Ergotamine—ABCB1—cerebellum—bipolar disorder	0.000184	0.00245	CbGeAlD
Ergotamine—Lisuride—HTR2A—bipolar disorder	0.000165	0.0183	CrCbGaD
Ergotamine—Bromocriptine—HTR2A—bipolar disorder	0.000153	0.0169	CrCbGaD
Ergotamine—ABCB1—brain—bipolar disorder	0.00015	0.00199	CbGeAlD
Ergotamine—HTR2C—Signaling Pathways—TAC1—bipolar disorder	1.12e-05	6.62e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—S100B—bipolar disorder	1.12e-05	6.6e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TCF7L2—bipolar disorder	1.12e-05	6.6e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ADM—bipolar disorder	1.11e-05	6.58e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NTRK2—bipolar disorder	1.11e-05	6.57e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—DRD2—bipolar disorder	1.11e-05	6.56e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—HTR2A—bipolar disorder	1.11e-05	6.55e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD3—bipolar disorder	1.11e-05	6.54e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HTR2C—bipolar disorder	1.1e-05	6.52e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD1—bipolar disorder	1.1e-05	6.52e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—GSK3A—bipolar disorder	1.1e-05	6.52e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD1—bipolar disorder	1.1e-05	6.49e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—HTR2A—bipolar disorder	1.09e-05	6.45e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HTR1A—bipolar disorder	1.09e-05	6.43e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TACR1—bipolar disorder	1.08e-05	6.41e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PDE4B—bipolar disorder	1.08e-05	6.41e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TSHB—bipolar disorder	1.08e-05	6.41e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NR1D1—bipolar disorder	1.08e-05	6.41e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NTRK1—bipolar disorder	1.08e-05	6.38e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—GSK3B—bipolar disorder	1.08e-05	6.37e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD4—bipolar disorder	1.07e-05	6.35e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NTRK2—bipolar disorder	1.07e-05	6.35e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TAC1—bipolar disorder	1.07e-05	6.33e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—POMC—bipolar disorder	1.07e-05	6.32e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD3—bipolar disorder	1.07e-05	6.32e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NTRK2—bipolar disorder	1.07e-05	6.31e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—HTR2A—bipolar disorder	1.07e-05	6.31e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—GSK3A—bipolar disorder	1.06e-05	6.29e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—INS—bipolar disorder	1.06e-05	6.28e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD3—bipolar disorder	1.06e-05	6.28e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—GSK3A—bipolar disorder	1.06e-05	6.26e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD1—bipolar disorder	1.05e-05	6.21e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HTR2C—bipolar disorder	1.05e-05	6.21e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—POMC—bipolar disorder	1.05e-05	6.21e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—S100B—bipolar disorder	1.05e-05	6.2e-05	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—POMC—bipolar disorder	1.04e-05	6.17e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NCAN—bipolar disorder	1.04e-05	6.13e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD4—bipolar disorder	1.04e-05	6.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—SNAP25—bipolar disorder	1.04e-05	6.13e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD4—bipolar disorder	1.03e-05	6.1e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NTRK2—bipolar disorder	1.02e-05	6.04e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD3—bipolar disorder	1.02e-05	6.02e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—SLC5A3—bipolar disorder	1.02e-05	6.01e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—GSK3A—bipolar disorder	1.01e-05	5.99e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—ADCY2—bipolar disorder	1.01e-05	5.98e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TCF7L2—bipolar disorder	1.01e-05	5.96e-05	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—POMC—bipolar disorder	1.01e-05	5.96e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—NRG1—bipolar disorder	1.01e-05	5.95e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HTR2A—bipolar disorder	1.01e-05	5.95e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NTRK1—bipolar disorder	1e-05	5.94e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HTR1A—bipolar disorder	1e-05	5.93e-05	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—POMC—bipolar disorder	1e-05	5.93e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—DRD2—bipolar disorder	1e-05	5.92e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—HTR2A—bipolar disorder	9.91e-06	5.86e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD4—bipolar disorder	9.88e-06	5.84e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TAC1—bipolar disorder	9.87e-06	5.84e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HTR1A—bipolar disorder	9.87e-06	5.83e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—NRG1—bipolar disorder	9.85e-06	5.83e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—ADCY2—bipolar disorder	9.76e-06	5.77e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—S100B—bipolar disorder	9.76e-06	5.77e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TCF7L2—bipolar disorder	9.73e-06	5.75e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TAC1—bipolar disorder	9.72e-06	5.75e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—ADCY2—bipolar disorder	9.71e-06	5.74e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HTR2A—bipolar disorder	9.69e-06	5.73e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD1—bipolar disorder	9.68e-06	5.73e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HTR2C—bipolar disorder	9.68e-06	5.73e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TCF7L2—bipolar disorder	9.68e-06	5.72e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HTR1A—bipolar disorder	9.66e-06	5.71e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—DRD2—bipolar disorder	9.66e-06	5.71e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NDUFV2—bipolar disorder	9.62e-06	5.69e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—DRD2—bipolar disorder	9.61e-06	5.68e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—POMC—bipolar disorder	9.59e-06	5.67e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD1—bipolar disorder	9.53e-06	5.64e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HTR2C—bipolar disorder	9.53e-06	5.64e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TAC1—bipolar disorder	9.51e-06	5.63e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—POMC—bipolar disorder	9.48e-06	5.6e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NTRK2—bipolar disorder	9.42e-06	5.57e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD3—bipolar disorder	9.38e-06	5.55e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—GSK3A—bipolar disorder	9.34e-06	5.52e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD1—bipolar disorder	9.33e-06	5.52e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HTR2C—bipolar disorder	9.33e-06	5.52e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKR1C4—bipolar disorder	9.32e-06	5.51e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—ADCY2—bipolar disorder	9.3e-06	5.5e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NTRK2—bipolar disorder	9.27e-06	5.48e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TCF7L2—bipolar disorder	9.26e-06	5.48e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NRG1—bipolar disorder	9.25e-06	5.47e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD3—bipolar disorder	9.23e-06	5.46e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CLOCK—bipolar disorder	9.2e-06	5.44e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—DRD2—bipolar disorder	9.2e-06	5.44e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—GSK3A—bipolar disorder	9.19e-06	5.43e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ADCY2—bipolar disorder	9.18e-06	5.43e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—POMC—bipolar disorder	9.15e-06	5.41e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—DRD4—bipolar disorder	9.1e-06	5.38e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—POMC—bipolar disorder	9.1e-06	5.38e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NTRK2—bipolar disorder	9.08e-06	5.37e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HTR2A—bipolar disorder	9.07e-06	5.36e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NTRK1—bipolar disorder	9.06e-06	5.36e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD3—bipolar disorder	9.04e-06	5.34e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HTR2A—bipolar disorder	9e-06	5.32e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—GSK3A—bipolar disorder	9e-06	5.32e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HTR1A—bipolar disorder	8.98e-06	5.31e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—TSHB—bipolar disorder	8.97e-06	5.3e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—TPH2—bipolar disorder	8.97e-06	5.3e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CACNB2—bipolar disorder	8.97e-06	5.3e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD4—bipolar disorder	8.96e-06	5.3e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HTR2A—bipolar disorder	8.88e-06	5.25e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—POMC—bipolar disorder	8.84e-06	5.23e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TAC1—bipolar disorder	8.84e-06	5.23e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—DPYD—bipolar disorder	8.82e-06	5.22e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—S100B—bipolar disorder	8.81e-06	5.21e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD4—bipolar disorder	8.77e-06	5.19e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NTRK1—bipolar disorder	8.75e-06	5.17e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—POMC—bipolar disorder	8.71e-06	5.15e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—POMC—bipolar disorder	8.7e-06	5.15e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NTRK1—bipolar disorder	8.7e-06	5.15e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD1—bipolar disorder	8.67e-06	5.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HTR2C—bipolar disorder	8.67e-06	5.13e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NRG1—bipolar disorder	8.61e-06	5.09e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—ADCY2—bipolar disorder	8.57e-06	5.07e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TCF7L2—bipolar disorder	8.54e-06	5.05e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—POMC—bipolar disorder	8.52e-06	5.04e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—S100B—bipolar disorder	8.5e-06	5.03e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—S100B—bipolar disorder	8.46e-06	5e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—ADCY2—bipolar disorder	8.43e-06	4.99e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NTRK2—bipolar disorder	8.43e-06	4.99e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TCF7L2—bipolar disorder	8.4e-06	4.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD3—bipolar disorder	8.4e-06	4.97e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NR1D1—bipolar disorder	8.37e-06	4.95e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—GSK3A—bipolar disorder	8.36e-06	4.94e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—DRD2—bipolar disorder	8.35e-06	4.94e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HTR2A—bipolar disorder	8.34e-06	4.93e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NTRK1—bipolar disorder	8.33e-06	4.93e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ADCY2—bipolar disorder	8.26e-06	4.88e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TCF7L2—bipolar disorder	8.23e-06	4.87e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CACNA1C—bipolar disorder	8.2e-06	4.85e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—DRD2—bipolar disorder	8.17e-06	4.83e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD4—bipolar disorder	8.15e-06	4.82e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—S100B—bipolar disorder	8.1e-06	4.79e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—POMC—bipolar disorder	8.03e-06	4.75e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NCAN—bipolar disorder	8e-06	4.73e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3C2A—bipolar disorder	7.99e-06	4.73e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—POMC—bipolar disorder	7.92e-06	4.68e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—POMC—bipolar disorder	7.9e-06	4.67e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—COMT—bipolar disorder	7.86e-06	4.65e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SLC5A3—bipolar disorder	7.84e-06	4.64e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—MAOA—bipolar disorder	7.8e-06	4.61e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NRG1—bipolar disorder	7.77e-06	4.6e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HTR2A—bipolar disorder	7.76e-06	4.59e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—POMC—bipolar disorder	7.74e-06	4.58e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NTRK1—bipolar disorder	7.68e-06	4.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ADCY2—bipolar disorder	7.67e-06	4.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TCF7L2—bipolar disorder	7.65e-06	4.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—DRD2—bipolar disorder	7.59e-06	4.49e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NTRK1—bipolar disorder	7.56e-06	4.47e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NRG1—bipolar disorder	7.5e-06	4.44e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NRG1—bipolar disorder	7.47e-06	4.42e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—S100B—bipolar disorder	7.47e-06	4.41e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NTRK1—bipolar disorder	7.4e-06	4.38e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CLOCK—bipolar disorder	7.35e-06	4.34e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—S100B—bipolar disorder	7.35e-06	4.34e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—GSK3B—bipolar disorder	7.3e-06	4.32e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—POMC—bipolar disorder	7.24e-06	4.28e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—INS—bipolar disorder	7.2e-06	4.26e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—S100B—bipolar disorder	7.19e-06	4.25e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—POMC—bipolar disorder	7.19e-06	4.25e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—SNAP25—bipolar disorder	7.17e-06	4.24e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TSHB—bipolar disorder	7.16e-06	4.23e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—TPH2—bipolar disorder	7.16e-06	4.23e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CACNB2—bipolar disorder	7.16e-06	4.23e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—GSK3B—bipolar disorder	7.15e-06	4.23e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NRG1—bipolar disorder	7.15e-06	4.23e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—POMC—bipolar disorder	7.09e-06	4.2e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—INS—bipolar disorder	7.05e-06	4.17e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—DPYD—bipolar disorder	7.04e-06	4.17e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HTR2A—bipolar disorder	7.01e-06	4.15e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NTRK1—bipolar disorder	6.87e-06	4.07e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HTR2A—bipolar disorder	6.77e-06	4e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HTR2A—bipolar disorder	6.73e-06	3.98e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—GSK3B—bipolar disorder	6.72e-06	3.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—S100B—bipolar disorder	6.68e-06	3.95e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—POMC—bipolar disorder	6.66e-06	3.94e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—INS—bipolar disorder	6.63e-06	3.92e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NRG1—bipolar disorder	6.59e-06	3.9e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CACNA1C—bipolar disorder	6.55e-06	3.87e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NRG1—bipolar disorder	6.48e-06	3.83e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HTR2A—bipolar disorder	6.44e-06	3.81e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3C2A—bipolar disorder	6.38e-06	3.77e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—MTHFR—bipolar disorder	6.35e-06	3.76e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NRG1—bipolar disorder	6.35e-06	3.75e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ADCY2—bipolar disorder	6.34e-06	3.75e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—bipolar disorder	6.3e-06	3.72e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—GSK3B—bipolar disorder	6.25e-06	3.7e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—POMC—bipolar disorder	6.2e-06	3.67e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—INS—bipolar disorder	6.17e-06	3.65e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HTR2A—bipolar disorder	5.94e-06	3.51e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NRG1—bipolar disorder	5.9e-06	3.49e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HTR2A—bipolar disorder	5.72e-06	3.38e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—SNAP25—bipolar disorder	5.72e-06	3.38e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CLOCK—bipolar disorder	5.67e-06	3.35e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—GSK3B—bipolar disorder	5.64e-06	3.34e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—POMC—bipolar disorder	5.6e-06	3.31e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—INS—bipolar disorder	5.57e-06	3.29e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TSHB—bipolar disorder	5.52e-06	3.27e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CACNB2—bipolar disorder	5.52e-06	3.27e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—TPH2—bipolar disorder	5.52e-06	3.27e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—GSK3B—bipolar disorder	5.45e-06	3.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—DPYD—bipolar disorder	5.44e-06	3.21e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—COMT—bipolar disorder	5.43e-06	3.21e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—GSK3B—bipolar disorder	5.42e-06	3.21e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—POMC—bipolar disorder	5.4e-06	3.2e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MAOA—bipolar disorder	5.39e-06	3.19e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—POMC—bipolar disorder	5.38e-06	3.18e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—INS—bipolar disorder	5.37e-06	3.18e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—INS—bipolar disorder	5.35e-06	3.16e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HTR2A—bipolar disorder	5.32e-06	3.14e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—GSK3B—bipolar disorder	5.19e-06	3.07e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—POMC—bipolar disorder	5.15e-06	3.04e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—INS—bipolar disorder	5.12e-06	3.03e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—POMC—bipolar disorder	5.08e-06	3e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ADCY2—bipolar disorder	5.06e-06	3e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CACNA1C—bipolar disorder	5.05e-06	2.99e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—INS—bipolar disorder	5.05e-06	2.99e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3C2A—bipolar disorder	4.92e-06	2.91e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—GSK3B—bipolar disorder	4.78e-06	2.83e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—POMC—bipolar disorder	4.74e-06	2.81e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—INS—bipolar disorder	4.72e-06	2.79e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—GSK3B—bipolar disorder	4.71e-06	2.78e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—POMC—bipolar disorder	4.67e-06	2.76e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—INS—bipolar disorder	4.64e-06	2.75e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—GSK3B—bipolar disorder	4.61e-06	2.73e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—POMC—bipolar disorder	4.57e-06	2.7e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—INS—bipolar disorder	4.55e-06	2.69e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SNAP25—bipolar disorder	4.42e-06	2.61e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MTHFR—bipolar disorder	4.39e-06	2.6e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—COMT—bipolar disorder	4.34e-06	2.57e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MAOA—bipolar disorder	4.31e-06	2.55e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—GSK3B—bipolar disorder	4.28e-06	2.53e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—POMC—bipolar disorder	4.25e-06	2.51e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—INS—bipolar disorder	4.22e-06	2.5e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ADCY2—bipolar disorder	3.91e-06	2.31e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—POMC—bipolar disorder	3.51e-06	2.08e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—bipolar disorder	3.51e-06	2.07e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—INS—bipolar disorder	3.49e-06	2.07e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—COMT—bipolar disorder	3.35e-06	1.98e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MAOA—bipolar disorder	3.32e-06	1.97e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—POMC—bipolar disorder	2.8e-06	1.66e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—INS—bipolar disorder	2.79e-06	1.65e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—bipolar disorder	2.71e-06	1.6e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—POMC—bipolar disorder	2.16e-06	1.28e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—INS—bipolar disorder	2.15e-06	1.27e-05	CbGpPWpGaD
